NCT06208540View on ClinicalTrials.gov

Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants

PHASE4CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

August 30, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

May 30, 2024

Conditions
Post-covid-19 Persistent Smell and Taste Disorders
Interventions
DRUG

Cerebrolysin

Cerebrolysin Dose:5 ml ampoule (1ml contains 215.2 mg cerebrolysin) once daily through intramuscular injection five times per week, for a total of 20 treatments (for 4 weeks), after which the cycle was repeated again for at least 6 weeks till a maximum of 24 weeks.

OTHER

olfactory and gustatory trainings

olfactory and gustatory trainings using oils of strong odors for the same time frame as for the drug intervention

Trial Locations (2)

71516

Assiut University Hospitals, Faculty of Medicine, Hospital of Neurology, Neurosurgery and Psychiatry, Assiut University Hospital, Assiut, Egypt, Asyut

Assiut University, Faculty of Medicine, Hospital of Neurology, Psychiatry and Neurosurgery, Asyut

All Listed Sponsors
lead

Sherifa Ahmed Hamed

OTHER

NCT06208540 - Clinical Characteristics and Treatment of Anosmia and Ageusia Due to SARS-CoV2 Variants | Biotech Hunter | Biotech Hunter